Henry Ford Health

Henry Ford Health Scholarly Commons
Behavioral Health Articles

Behavioral Health Services / Psychiatry

9-12-2020

The diagnosis of severe obsessions in the setting of kratom
withdrawal and treatment with lorazepam: Case report
Ibrahim M. Sablaban
Henry Ford Health, isablab1@hfhs.org

Mohan Gautam
Henry Ford Health, mgautam1@hfhs.org

Follow this and additional works at: https://scholarlycommons.henryford.com/behavioralhealth_articles

Recommended Citation
Sablaban IM, and Gautam M. The diagnosis of severe obsessions in the setting of kratom withdrawal and
treatment with lorazepam: Case report. J Addict Dis 2020.

This Article is brought to you for free and open access by the Behavioral Health Services / Psychiatry at Henry Ford
Health Scholarly Commons. It has been accepted for inclusion in Behavioral Health Articles by an authorized
administrator of Henry Ford Health Scholarly Commons.

See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/344251025

The diagnosis of severe obsessions in the setting of kratom withdrawal and
treatment with lorazepam
Article in Journal of Addictive Diseases · September 2020
DOI: 10.1080/10550887.2020.1813357

CITATIONS

READS

0

18

3 authors, including:
Mohan Gautam

Ibrahim Sablaban

Henry Ford Hospital

Henry Ford Health System

11 PUBLICATIONS 55 CITATIONS

6 PUBLICATIONS 10 CITATIONS

SEE PROFILE

Some of the authors of this publication are also working on these related projects:

COVID-19 View project

Psychopharmacological analyses of levomilnacipran View project

All content following this page was uploaded by Mohan Gautam on 17 September 2020.
The user has requested enhancement of the downloaded file.

SEE PROFILE

Journal of Addictive Diseases

ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/wjad20

The diagnosis of severe obsessions in the setting
of kratom withdrawal and treatment with
lorazepam: Case report
Ibrahim M. Sablaban & Mohan Gautam
To cite this article: Ibrahim M. Sablaban & Mohan Gautam (2020): The diagnosis of severe
obsessions in the setting of kratom withdrawal and treatment with lorazepam: Case report, Journal
of Addictive Diseases, DOI: 10.1080/10550887.2020.1813357
To link to this article: https://doi.org/10.1080/10550887.2020.1813357

Published online: 12 Sep 2020.

Submit your article to this journal

View related articles

View Crossmark data

Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=wjad20

JOURNAL OF ADDICTIVE DISEASES
https://doi.org/10.1080/10550887.2020.1813357

The diagnosis of severe obsessions in the setting of kratom withdrawal and
treatment with lorazepam: Case report
Ibrahim M. Sablaban, DO

and Mohan Gautam, DO

Department of Psychiatry, Henry Ford Hospital/Wayne State University, Detroit, MI, USA
ABSTRACT

Commercially available Kratom (Mitragyna speciosa) is a dietary supplement that has gained
popularity in the United States for its psychoactive effects and potential medicative properties as an opioid receptor agonist. Likewise, sudden discontinuation may be accompanied
by an opioid-like withdrawal. We present the first case in the literature of the withdrawal
manifesting in disturbing obsessive thoughts after the substance was used as an opioid
replacement treatment by our patient, as well as the first case where lorazepam is utilized
for mitigation of these thoughts.

Introduction

Commercially available Kratom (Mitragyna speciosa) is a dietary supplement that has gained
popularity in the United States (US) for its psychoactive effects and potential medicative properties. More recently, it has become noted for its
use as a self-driven treatment for opioid dependence and withdrawal, although no evidence supports such use.1 Kratom is however known to
cause a withdrawal syndrome that mirrors opiate
withdrawal,2 and while psychological sequelae
have also been noted,3 this is the first noted case
where obsessions emerge as a feature of kratom withdrawal.
Case

The patient was a 27-year-old male who came to
the emergency department after attempting to
wean himself off of kratom. The patient had
started taking kratom to get off of oxycodone
which he started after a back injury over the
course of several months. Notably, he had no
prior history of illicit drug use prior to his injury
and experimentation with kratom. The dosage of
oxycodone he would use was variable, but typically 10 milligrams (mgs) thrice daily. He had
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switched to using kratom for three weeks before
presenting, but reported mistakenly taking two to
three times the amount recommended by the
supplier, a popular online website; upwards of 15
grams three times a day. After two weeks of use
the patient noticed that he had a heightened state
of anxiety taking kratom, and ultimately realized
he was taking too much. Over the course of two
days he attempted to wean himself off.
Seventeen hours after his last dose he reported
having a surge of anxiety and intrusive obsessive
thoughts. These included thoughts about violently
sexually assaulting female relatives and graphic
homicidal ideation toward male friends. He had
no history of violence and was extremely disturbed by the ideas. Lab values including a basic
metabolic panel, complete blood cell count and
thyroid stimulating hormone were unremarkable,
as were a urinalysis and urine drug screen. He
also appeared to be in mild withdrawal per our
Clinical Opiate Withdrawal Score (COWS),
which yielded 8, with evident rhinorrhea and lacrimation present. He was given 2 mg of intravenous lorazepam which within half an hour had
completely resolved the obsessions. No subsequent dose was needed. Ultimately he went to a
substance use rehabilitation facility.

Department of Psychiatry, Henry Ford Hospital/Wayne State University, One Ford Place,

2

I. M. SABLABAN AND M. GAUTAM

Discussion & Conclusion

Kratom has been widely used for both traditional
medicine and religious practice in Southeast Asia
for hundreds of years, but has been long appreciated to have addictive potential.4 Although it
contains multiple psychoactive compounds which
agonize l-opioid and presumably a2-adrenergic
receptors, it’s pharmacology is poorly understood.1,4 Adding to the difficulty in studying
commercially available kratom are variety in
strains and increasingly, the disuniformity in
composition. Evidence exists of compounds
which may produce more euphoria when
consumed (i.e. 7-hydroxymitragynine) being
artificially
increased
in
commercially
5
available kratom.
There is a paucity of literature on psychiatric
symptoms associated with kratom withdrawal. A
2018 study of chronic users in Malaysia sought to
assess depression and anxiety in withdrawal, both
of which were noted to be mildly increased.3 The
study examined those who consumed the leaves
brewed as a tea - doubtfully equivalent to those
consuming kratom dietary supplements for opioid replacement or self-treatment. Ours is the
first case of obsessions manifesting with kratom
withdrawal in the literature. Such a presentation
may have been influenced by markedly higher
intake and fast taper off of the substance. It is
notable that lorazepam resulted in a complete
resolution of the obsessions.
Opioid replacement treatment was briefly considered early in his presentation, however as our
patient’s withdrawal symptoms per COWS
remained consistent at a mild designation, concerns about treating him with buprenorphine
arose as the partial l-opioid agonist might have
provoked a more severe withdrawal. Additionally,
although physically dependent in the recent
weeks, the patient had not met criteria for
Opioid Use Disorder per The Diagnostic and
Statistical Manual of Mental Disorders 5, and
thus methadone treatment was not indicated. His
prior opioid use was prescribed, and posed little
to no appreciable problem to him aside from
concerns of remaining on the medication chronically. His brief attempt to wean himself off with
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an erroneous dosing of kratom, while not medically sound and problematic, had not fulfilled use
disorder criteria.
Given the climate of opioid use disorders in
the US and limited numbers of physicians and
providers who treat substance use disorders, kratom is emerging as a way to circumvent healthcare providers. As use grows and the potential
for higher dosing and withdrawal increases, it is
important that clinicians be aware of the varied
manifestations of kratom withdrawal.
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